Zhuhai Rundu Pharmaceutical Co Ltd Class A (SHE:002923) — Market Cap & Net Worth
Market Cap & Net Worth: Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923)
Zhuhai Rundu Pharmaceutical Co Ltd Class A (SHE:002923) has a market capitalization of $479.27 Million (CN¥3.28 Billion) as of June 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #12627 globally and #3732 in its home market, demonstrating a -1.51% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zhuhai Rundu Pharmaceutical Co Ltd Class A's stock price CN¥9.78 by its total outstanding shares 334893286 (334.89 Million). Review 002923 total debt and obligations to assess the company's total debt and financial obligations.
Zhuhai Rundu Pharmaceutical Co Ltd Class A Market Cap History: 2018 to 2026
Zhuhai Rundu Pharmaceutical Co Ltd Class A's market capitalization history from 2018 to 2026. Data shows growth from $370.35 Million to $479.27 Million (5.09% CAGR).
Zhuhai Rundu Pharmaceutical Co Ltd Class A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zhuhai Rundu Pharmaceutical Co Ltd Class A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.40x
Zhuhai Rundu Pharmaceutical Co Ltd Class A's market cap is 0.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
11.72x
Zhuhai Rundu Pharmaceutical Co Ltd Class A's market cap is 11.72 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $370.35 Million | $1.04 Billion | $106.84 Million | 0.35x | 3.47x |
| 2019 | $419.84 Million | $1.36 Billion | $118.90 Million | 0.31x | 3.53x |
| 2020 | $397.81 Million | $1.25 Billion | $135.86 Million | 0.32x | 2.93x |
| 2021 | $616.42 Million | $1.19 Billion | $139.77 Million | 0.52x | 4.41x |
| 2022 | $586.10 Million | $1.37 Billion | $155.48 Million | 0.43x | 3.77x |
| 2023 | $593.39 Million | $1.29 Billion | $66.90 Million | 0.46x | 8.87x |
| 2024 | $467.51 Million | $1.18 Billion | $39.88 Million | 0.40x | 11.72x |
Competitor Companies of 002923 by Market Capitalization
Companies near Zhuhai Rundu Pharmaceutical Co Ltd Class A in the global market cap rankings as of June 19, 2026.
Key companies related to Zhuhai Rundu Pharmaceutical Co Ltd Class A by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #555 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #601 globally with a market cap of $45.20 Billion USD ( CN¥308.87 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #555 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.94 |
| #601 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.20 Billion | CN¥48.42 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Zhuhai Rundu Pharmaceutical Co Ltd Class A Historical Marketcap From 2018 to 2026
Between 2018 and today, Zhuhai Rundu Pharmaceutical Co Ltd Class A's market cap moved from $370.35 Million to $ 479.27 Million, with a yearly change of 5.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥479.27 Million | -19.51% |
| 2025 | CN¥595.42 Million | +27.36% |
| 2024 | CN¥467.51 Million | -21.21% |
| 2023 | CN¥593.39 Million | +1.24% |
| 2022 | CN¥586.10 Million | -4.92% |
| 2021 | CN¥616.42 Million | +54.95% |
| 2020 | CN¥397.81 Million | -5.25% |
| 2019 | CN¥419.84 Million | +13.36% |
| 2018 | CN¥370.35 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Zhuhai Rundu Pharmaceutical Co Ltd Class A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $479.27 Million USD |
| MoneyControl | $479.27 Million USD |
| MarketWatch | $479.27 Million USD |
| marketcap.company | $479.27 Million USD |
| Reuters | $479.27 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zhuhai Rundu Pharmaceutical Co Ltd Class A
Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular; and pellets for excipient, antiulcerative, diabetes drug, anti-inflammatory, and anti-anginals. The company is also involved in the process development, qu… Read more